ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

R.J. Motzer; C.-H. Lee; H. Emamekhoo; M. Matrana; I. Percent; J.J. Hsieh; A. Hussain; U.N. Vaishampayan; R. Graham; S. Liu; S. McCune; M. Shaheen; H. Parmar; Y. Shen; S.H. Whiting; N.M. Tannir

Journal ArticleOPEN ACCESS

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Motzer R
Lee C
Emamekhoo H
et al.

Annals of Oncology (2019) 30 v889-v890

DOI: 10.1093/annonc/mdz394.048

N/ACitations

28Readers

Abstract

vs placebo (pbo) 1 E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Cite

CITATION STYLE

APA

Motzer, R. J., Lee, C.-H., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., … Tannir, N. M. (2019). ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). Annals of Oncology, 30, v889–v890. https://doi.org/10.1093/annonc/mdz394.048

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Abstract

Cite

Register to see more suggestions